Literature DB >> 20556633

Cholesteryl ester transfer protein and its inhibition.

Olaf Weber1, Hilmar Bischoff, Carsten Schmeck, Michael-Friedrich Böttcher.   

Abstract

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. Inhibition of CETP is considered a potential approach to treat dyslipidemia. However, discussions regarding the role of CETP-mediated lipid transfer in the development of atherosclerosis and CETP inhibition as a potential strategy for prevention of atherosclerosis have been controversial. Although many animal studies support the hypothesis that inhibition of CETP activity may be beneficial, negative phase III studies on clinical endpoints with the CETP inhibitor torcetrapib challenged the future perspectives of CETP inhibitors as potential therapeutic agents. The review provides an update on current understanding of the molecular mechanisms involved in CETP activity and its inhibition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556633     DOI: 10.1007/s00018-010-0418-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  118 in total

Review 1.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

2.  Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue.

Authors:  F Benoist; P Lau; M McDonnell; H Doelle; R Milne; R McPherson
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

3.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

4.  Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia.

Authors:  M Guérin; P J Dolphin; M J Chapman
Journal:  Arterioscler Thromb       Date:  1994-05

5.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

Review 6.  Scavenger receptor BI and cholesterol trafficking.

Authors:  D L Williams; M A Connelly; R E Temel; S Swarnakar; M C Phillips; M de la Llera-Moya; G H Rothblat
Journal:  Curr Opin Lipidol       Date:  1999-08       Impact factor: 4.776

7.  Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.

Authors:  Xiayang Qiu; Anil Mistry; Mark J Ammirati; Boris A Chrunyk; Ronald W Clark; Yang Cong; Jeffrey S Culp; Dennis E Danley; Thomas B Freeman; Kieran F Geoghegan; Matthew C Griffor; Steven J Hawrylik; Cheryl M Hayward; Preston Hensley; Lise R Hoth; George A Karam; Maruja E Lira; David B Lloyd; Katherine M McGrath; Kim J Stutzman-Engwall; Ann K Subashi; Timothy A Subashi; John F Thompson; Ing-Kae Wang; Honglei Zhao; Andrew P Seddon
Journal:  Nat Struct Mol Biol       Date:  2007-01-21       Impact factor: 15.369

8.  Biological evidence for inheritance of exceptional longevity.

Authors:  Gil Atzmon; Marielisa Rincon; Pegah Rabizadeh; Nir Barzilai
Journal:  Mech Ageing Dev       Date:  2005-02       Impact factor: 5.432

9.  Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein.

Authors:  David Cunningham; Wen Lin; Lise R Hoth; Dennis E Danley; Roger B Ruggeri; Kieran F Geoghegan; Boris A Chrunyk; James G Boyd
Journal:  Bioconjug Chem       Date:  2008-07-23       Impact factor: 4.774

10.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Authors:  Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

View more
  8 in total

1.  Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity.

Authors:  Mette Soerensen; Serena Dato; Qihua Tan; Mikael Thinggaard; Rabea Kleindorp; Marian Beekman; H Eka D Suchiman; Rune Jacobsen; Matt McGue; Tinna Stevnsner; Vilhelm A Bohr; Anton J M de Craen; Rudi G J Westendorp; Stefan Schreiber; P Eline Slagboom; Almut Nebel; James W Vaupel; Kaare Christensen; Lene Christiansen
Journal:  Age (Dordr)       Date:  2012-01-12

2.  Cholesteryl ester transfer protein (CETP) -629C/A polymorphism and it's effects on the serum lipid levels in metabolic syndrome patients.

Authors:  M Akbarzadeh; T Hassanzadeh; M Saidijam; R Esmaeili; Sh Borzouei; M Hajilooi; H Mahjub; M Paoli
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

Review 3.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

4.  CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Authors:  François Briand; Quentin Thieblemont; Agnès André; Khadija Ouguerram; Thierry Sulpice
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

5.  Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Authors:  Olaf Weber; Stefan Willmann; Hilmar Bischoff; Volkhart Li; Alexandros Vakalopoulos; Klemens Lustig; Frank-Thorsten Hafner; Roland Heinig; Carsten Schmeck; Klaus Buehner
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 6.  Resveratrol in cardiovascular disease: what is known from current research?

Authors:  Hong Wang; Yue-Jin Yang; Hai-Yan Qian; Qian Zhang; Hui Xu; Jian-Jun Li
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

7.  New Diterpenes from Cultures of the Fungus Engleromyces goetzii and Their CETP Inhibitory Activity.

Authors:  Yang Wang; Ling Zhang; Fang Wang; Zheng-Hui Li; Ze-Jun Dong; Ji-Kai Liu
Journal:  Nat Prod Bioprospect       Date:  2015-04-08

8.  Genistein as a potential inducer of the anti-atherogenic enzyme paraoxonase-1: studies in cultured hepatocytes in vitro and in rat liver in vivo.

Authors:  Charlotte Schrader; Insa M A Ernst; Heike Sinnecker; Sebastian T Soukup; Sabine E Kulling; Gerald Rimbach
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.